On January 13, 2025, Aerin Medical, a medical device company focused on expanding access to meaningful relief for millions of patients suffering from chronic ENT conditions, announced the successful completion of two significant financial transactions. These transactions position Aerin Medical to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin's major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital.

Wilson Sonsini Goodrich & Rosati advised Aerin on both transactions. The Wilson Sonsini team included:

Corporate - Venture Capital 
Elton Satusky
Victor MacDiarmid
Alan Jiang

Corporate Finance
John Mao
Joseph Catapano
Eaton Liu

For more information, please see the press release.